Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment.

CONCLUSION: The optimal response to DMF is mediated by a shift to antiinflammatory and immunoregulatory profile, which puts forward Th1-like Th17 lymphocytes as a potential early biomarker of treatment response. PMID: 31066225 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31066225?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - May 6, 2019 Category: Neuroscience Authors: Mansilla MJ, Navarro-Barriuso J, Presas-Rodríguez S, Teniente-Serra A, Quirant-Sánchez B, Ramo-Tello C, Martínez-Cáceres EM Tags: CNS Neurosci Ther Source Type: research

More News: Brain | Multiple Sclerosis | Neurology | Neuroscience | Study